JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.14 4.59

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.09

Max

1.18

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Sell
12-Monats-Prognose	+238.98% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-29M 73M
Vorheriger Eröffnungskurs	-3.45
Vorheriger Schlusskurs	1.14

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6. Feb. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6. Feb. 2026, 21:17 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. Feb. 2026, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6. Feb. 2026, 21:13 UTC

Ergebnisse

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6. Feb. 2026, 21:13 UTC

Ergebnisse

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6. Feb. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6. Feb. 2026, 20:34 UTC

Ergebnisse

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6. Feb. 2026, 20:27 UTC

Ergebnisse

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6. Feb. 2026, 20:24 UTC

Market Talk

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6. Feb. 2026, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6. Feb. 2026, 19:48 UTC

Ergebnisse

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6. Feb. 2026, 19:30 UTC

Akquisitionen, Fusionen, Übernahmen

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6. Feb. 2026, 19:17 UTC

Market Talk

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6. Feb. 2026, 18:50 UTC

Ergebnisse

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6. Feb. 2026, 18:47 UTC

Market Talk

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6. Feb. 2026, 18:34 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6. Feb. 2026, 17:58 UTC

Ergebnisse

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Global Equities Roundup: Market Talk

6. Feb. 2026, 17:52 UTC

Market Talk

Ergebnisse

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. Feb. 2026, 17:18 UTC

Market Talk

Canada's Bizarre Jobs Report Points to Growing Labor Slack -- Market Talk

6. Feb. 2026, 17:09 UTC

Market Talk

Dollar on Path to Snap Weekly Losing Streak -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

238.98% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 238.98%

Hoch 4 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.